Antigen News and Research

RSS

Discovery of genetic cause for primary biliary cirrhosis

Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.

27 May 2009

Research offers insight into why some prostate cancer returns

The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.

27 May 2009

ImmunoVaccine Technologies partners with FIT Biotech to advance therapeutic HIV vaccine

ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based , clinical stage company that develops DNA vaccines. This research will formulate FIT Biotech's GTU MultiHIV DNA plasmid with IVT's DepoVax vaccine delivery system to advance a therapeutic HIV vaccine.

26 May 2009

HHS directs $1 billion towards commercial-scale production of a candidate vaccine for H1N1

HHS Secretary Kathleen Sebelius has announced that the department will take important steps necessary to prepare for potential commercial-scale production of a candidate vaccine for the novel Influenza A ( H1N1).

24 May 2009

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).

20 May 2009

Recommendations by experts to WHO on influenza A (H1N1) vaccines

Current epidemiological information suggests that the influenza A (H1N1) virus transmissibility potential is at least comparable to that of seasonal influenza viruses, with ability to sustain community spread. There is therefore no reason to expect that ongoing spread of the virus will stop.

19 May 2009

Computer simulation captures immune response to flu

Researchers have successfully tested first the first time a computer simulation of major portions of the body's immune reaction to influenza type A, with implications for treatment design and preparation ahead of future pandemics, according to work accepted for publication, and posted online, by the Journal of Virology.

18 May 2009

Low oxygen levels in prostate tumors can predict recurrence

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.

17 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

New insights into immune exhaustion

A main reason why viruses such as HIV or hepatitis C persist despite a vigorous initial immune response is exhaustion. The T cells, or white blood cells, fighting a chronic infection eventually wear out.

13 May 2009

New mathematical model predicts immune response to influenza A virus

Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1). This model examines the contributions of specific sets of immune cells in fighting influenza A virus.

13 May 2009

Urologists say don’t give up on prostate cancer screening just yet

What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.

13 May 2009

Fat capsules carry markers for deadly prostate cancer

Tiny bubbles of fat in urine hold molecules that could predict whether prostate cancer is aggressive, according to research published in the British Journal of Cancer today (Wednesday).

12 May 2009

Money from Bill and Melinda Gates will help beat Dengue fever in Australia

The University of Queensland (UQ) has won a grant of $100,000 grant from the Bill and Melinda Gates Foundation to fight dengue and other mosquito-borne diseases.

11 May 2009

Study reveals current multi-component vaccines may need reworking

Current strategies for designing vaccines against HIV and cancers, for instance, may enable some components in multi-component vaccines to cancel the effect of others on the immune system, eliminating their ability to provide protection, according to an article to be published shortly in the Proceedings of the National Academy of Sciences (PNAS).

7 May 2009

Discovery of process that controls T cell growth

Identifying one of the processes that plays a role in naïve and memory T-cells' growth and production could one day lead to better vaccines and possibly more effective cancer immunotherapy, said researchers at Baylor College of Medicine and Texas Children's Hospital in a report that appears in the current edition of Nature Immunology.

3 May 2009

Statins can lower PSA levels in men with prostate cancer

Beyond lowering cholesterol, statin medications have been found to have numerous other health benefits, including lowering a healthy man's risk of developing advanced prostate cancer, as well as lowering his prostate-specific antigen (PSA) levels.

30 Apr 2009

Discovery of possible preventative therapy for type 1 diabetes

Scientists believe they may have found a preventative therapy for type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.

29 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009